中国临床药理学杂志2025，Vol.41Issue(22)：3255-3261,7.DOI:10.13699/j.cnki.1001-6821.2025.22.016
索拉非尼心脏毒性的分子机制及防治策略研究进展
Research progress on the molecular mechanisms of sorafenib-induced cardiotoxicity and preventive strategies
摘要
Abstract
As a multi-target tyrosine kinase inhibitor,sorafenib is the core therapeutic drug for advanced hepatocellular carcinoma,renal cell carcinoma and differentiated thyroid cancer.However,its cardiotoxicity significantly limits clinical application,mainly manifests in hypertension,myocardial ischemia,heart failure,arrhythmia,and thrombosis/hemorrhage events,which seriously affect the patient's prognosis.This paper deeply explores the molecular mechanisms of sorafenib inducing cardiotoxicity,including key pathways such as oxidative stress and mitochondrial dysfunction,autophagy imbalance,ribonucleic acid binding motif protein 20(RBM20)mediated gene splicing abnormalities,calcium homeostasis imbalance and myocardial electrophysiological abnormalities;at the same time,a systematic summary of clinical prevention and treatment strategies,covering monitoring and intervention measures for adverse reactions such as hypertension and heart failure,as well as research progress in experimental therapeutic drugs.关键词
索拉非尼/心脏损伤/氧化应激/RNA结合基序蛋白20/钙稳态失衡Key words
sorafenib/cardiotoxicity/oxidative stress/RNA-binding motif protein 20/calcium homeostasis imbalance分类
医药卫生引用本文复制引用
刘志伟,戴子茹,李新忠,汤爽,孙东升,王敏,肖航,李文兰,孙桂波..索拉非尼心脏毒性的分子机制及防治策略研究进展[J].中国临床药理学杂志,2025,41(22):3255-3261,7.基金项目
海南省重点研发基金资助项目(ZDYF2022SHFZ325) （ZDYF2022SHFZ325）
